Table 1.
Patients’ demographic and clinical characteristics at baseline
| Variable | Value |
|---|---|
| Demographic parameters | |
| Age (years) | 45 (±14.6) |
| Female/male, n (%) | 8 (53)/7 (47) |
| Age onset of psoriasis (years) | 23 (±15) |
| Psoriasis disease duration (years) | 18 (±12) |
| Age onset of PsA (years) | 35 (±15) |
| PsA disease duration (years) | 10 (±9.6) |
| Previous sDMARDs, n (%) | 3 (20) |
| Concomitant sDMARDs (methotrexate), n (%) | 4 (27) |
| Currently taken corticosteroids, n (%) | 1 (7) |
| Clinical parameters, physician’s assessment | |
| aCCP+, n (%) | 0 |
| RF+, n (%) | 1 (7) |
| ESR (mm/h) | 27 (±11) |
| CRP (mg/L) | 19 (±10.4) |
| DAS28-ESR | 4.9 (±1) |
| DAS28-CRP | 4.7 (±0.9) |
| TJC 68 | 11.5 (±11) |
| SJC 66 | 6.9 (±7.4) |
| Dactylitis (0–20) | 1.1 (±1.8) |
| Enthesitis (0–6) | 1.6 (±1.6) |
| Nail (0–10) | 5 (±3.8) |
| PASI (0–72) | 4.5 (±4.6) |
| Clinical parameters, patient-reported | |
| Stiffness (minutes) | 46 (±35.9) |
| Pain (0–10) | 5.9 (±3.1) |
| GVAS (0 − 100) | 56 (±28.6) |
| Fatigue (0–10) | 5.9 (±2.8) |
| HAQ (0–3) | 0.9 (±0.7) |
| DLQI (0–30) | 4.8 (±7.2) |
| PsAQol (0–20) | 8.6 (±5.7) |
Results are presented as mean ± SD, median (IQR) or percentage. Dactylitis, the number of affected digits. Enthesitis score is based on the Leeds enthesitis index. Nail, the number of affected nails on the hands. Stiffness is early morning stiffness. Pain scale ranges from 0 = no pain to 10 = pain as bad as it could be. The visual analogue scale for global health (GVAS) ranges from 0 = worst imaginable health state to 100 = best imaginable health state. The fatigue scale ranges from 0 = no fatigue to 10 = fatigue as bad as it could be. The health assessment questionnaire HAQ scale ranges from 0 = no difficulty to 3 = unable to perform activity. PsA psoriatic arthritis, aCCP antibodies against cyclic citrullinated peptides, RF rheumatoid factor, sDMARD synthetic disease-modifying antirheumatic drug, aCCP antibodies against cyclic citrullinated peptides, RF rheumatiod factor, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28-ESR/CRP disease activity score based on a 28-joint assessment of pain or swelling using the ESR/CRP-based formula (www.das-score.nl), TJC tender joint count, SJC swollen joint count, PASI psoriasis area and severity index, DLQI dermatology life quality index, PsAQol psoriatic arthritis-specific quality of life score